ERBB2 and non-small cell lung carcinoma: Given that the outcome for NSCLC patients with uncommon EGFR or HER2 mutations remains poor, with only a moderate at best benefit conferred by treatment with EGFR-TKIs or immune-checkpoint inhibitors and with the rarity of coexisting actionable mutations, novel therapies that improve outcome in these patients are urgently needed.